Regeneron up as prospective COVID-19 trial results show reduced medical visits

• Regeneron (NASDAQ:REGN) is up 2.5% after hours after it announced prospective results from its ongoing Phase 2/3 seamless trial of its COVID-19 antibody drug.
• The trial prospectively shows that the REGN-COV2 antibody cocktail "significantly reduced virus levels and the need for further medical attention," the company says.
• The new data involved an additional 524 patients and met its clinical endpoint of reducing medical visits.
• It's shared the results with the FDA, which is evaluating a possible Emergency Use Authorization.
• Treatment with REGN-COV2 reduced COVID-19-related medical visits by 57% - and by 72% in patients with one or more risk factors.
• But as CNBC's Meg Tirrell notes, with Regeneron securing their own manufacturing, there's only 50,000 doses available.
• https://seekingalpha.com/news/3627869-regeneronplus-2_5-prospective-covidminus-19-trial-results-show-reduced-medical-visits